The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

The Washington Post recently reported that a new analysis of 19 studies of long-acting asthma medicines, such as Advair and Servent, shows that the risk of hospitalization and death is substantially increased over those who used placebos.

“What we have here is a drug that increases the number of people who will die from the disease it is treating,” said lead author Shelley Salpeter of Stanford University.

The authors of the new analysis estimate that GlaxoSmithKline’s Advair Diskus “may be responsible” for up to 4,000 of the 5,000 asthma-related deaths each year in the U.S.

Comments are closed.

Of Interest